KD025 is a ROCK2 inhibitor currently being tested in clinical trials for the treatment of fibrotic
lung diseases. The therapeutic effects of KD025 are partly due to its inhibition of profibrotic …

Despite two FDA-approved anti-fibrotic drug options, most fibrotic lung diseases remain
progressive even on current therapy. Thus, an unmet need remains the development of …

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that leads to respiratory decline
due to scarring and thickening of lung tissues. Multiple pathways contribute to the fibrotic …

Dysfunctional endothelial cell (EC) barrier and increased lung vascular permeability is a
cardinal feature of acute lung injury and sepsis that may result in a pathophysiological …

Increased pulmonary vascular permeability is a hallmark of acute lung injury (ALI). Connexin
40 (Cx40) is a gap junctional protein abundantly present in the lung microvascular …

RATIONALE Rho-Associated Coiled-Coil Kinases (ROCK1 and ROCK2) are regulators of
the actomyosin cytoskeleton and function as central downstream mediators of multiple pro …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal lung disease. Rho-
associated protein kinases (ROCK) 1/2 are promising therapeutic targets for the treatment of …

Transforming growth factor (TGF)-β-induced myofibroblast transformation and alterations in
mesenchymal-epithelial interactions contribute to chronic lung diseases such as chronic …

Increased NADP reduced (NADPH) oxidase 4 (Nox4) and reduced expression of the
nuclear hormone receptor peroxisome proliferator-activated receptor γ (PPARγ) contribute to …

Rho-associated coiled-coil kinases (ROCKs), downstream effectors of the Rho family
GTPases, play a central role in the regulation of actin cytoskeleton dynamics. They regulate …